Investing.com - Cellectis reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Cellectis announced earnings per share of $-0.33 on revenue of $13.9M. Analysts polled by Investing.com anticipated EPS of $-0.7811 on revenue of $7.25M.
Cellectis shares are down 28.64% from the beginning of the year and are trading at $19.31 , down-from-52-week-high.They are under-performing the Nasdaq which is down 1.28% from the start of the year.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by AbbVie on Wednesday, February 3, 2021, who reported EPS of $2.92 on revenue of $13.86B, compared to forecasts EPS of $2.85 on revenue of $13.7B.
Merck&Co had missed expectations on Thursday, February 4, 2021 with fourth quarter EPS of $1.32 on revenue of $12.51B, compared to forecast for EPS of $1.38 on revenue of $12.67B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar